Literature DB >> 28210105

Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer.

Caroline Wilson1, Sarah J Danson1.   

Abstract

Lung cancer is the most common cancer worldwide, with 1.3 million new cases diagnosed every year. Non-small-cell lung carcinoma (NSCLC) has previously had a very poor prognosis with few effective therapies; however, research has identified that it is associated with a high rate of expression of epidermal growth factor receptor (EGFR) tyrosine kinase. This has led to discoveries in drug manipulation of this receptor, to provide effective new therapies against NSCLC. Gefitinib is a small molecule kinase inhibitor which inhibits the cytoplasmic domain of the EGFR; the evidence behind its use and future role is presented in this review.

Entities:  

Keywords:  cigarette smoking; epidermal growth factor receptor; gefitinib; non-small-cell lung carcinoma; tyrosine kinase

Year:  2010        PMID： 28210105      PMCID： PMC5312463          DOI： 10.2147/lctt.s9974

Source DB:  PubMed          Journal:  Lung Cancer (Auckl)        ISSN： 1179-2728


  84 in total

1.  Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Authors:  David M Jackman; Beow Y Yeap; Lecia V Sequist; Neal Lindeman; Alison J Holmes; Victoria A Joshi; Daphne W Bell; Mark S Huberman; Balazs Halmos; Michael S Rabin; Daniel A Haber; Thomas J Lynch; Matthew Meyerson; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

2.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

3.  Practical management of patients with non-small-cell lung cancer treated with gefitinib.

Authors:  Neelam T Shah; Mark G Kris; William Pao; Leslie B Tyson; Barbara M Pizzo; Murk-Hein Heinemann; Leah Ben-Porat; Dana L Sachs; Robert T Heelan; Vincent A Miller
Journal:  J Clin Oncol       Date:  2004-11-22       Impact factor: 44.544

4.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

Review 5.  Interstitial lung disease in lung cancer: separating disease progression from treatment effects.

Authors:  Sarah Danson; Fiona Blackhall; Paul Hulse; Malcolm Ranson
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

Review 7.  Overview of gefitinib in non-small cell lung cancer: an Asian perspective.

Authors:  Haiyi Jiang
Journal:  Jpn J Clin Oncol       Date:  2008-12-16       Impact factor: 3.019

8.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

9.  Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.

Authors:  Riichiroh Maruyama; Yutaka Nishiwaki; Tomohide Tamura; Nobuyuki Yamamoto; Masahiro Tsuboi; Kazuhiko Nakagawa; Tetsu Shinkai; Shunichi Negoro; Fumio Imamura; Kenji Eguchi; Koji Takeda; Akira Inoue; Keisuke Tomii; Masao Harada; Noriyuki Masuda; Haiyi Jiang; Yohji Itoh; Yukito Ichinose; Nagahiro Saijo; Masahiro Fukuoka
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

10.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.